Use of second-generation antipsychotic agents for sleep and sedation: A provider survey

Sleep

Volumn 36, Issue 4, 2013, Pages 597-600

  Hermes, Eric D A ^a,c   Michael Sernyak, ^a,b   Rosenheck, Robert ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Abraham Ribicoff Research Facilities   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Atypical antipsychotics; Decision making; Hypnotic; Off label; Pharmacoepidemiology

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; DECISION MAKING; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; PATIENT PREFERENCE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SLEEP;

ATYPICAL ANTIPSYCHOTICS; DECISION-MAKING; HYPNOTIC; OFF-LABEL; PHARMACOEPIDEMIOLOGY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DIBENZOTHIAZEPINES; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84875728892     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.2554     Document Type: Article

References (11)

1. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep 1999;22:S347-53.
2. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27:1441.
3. Linden M, Thiels C. Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics. Pharmacopsychiatry 2001;34:150-4.
4. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Ann Clin Psychiatry 2008;20:15-20.
5. Hermes EDA, Sernyak M, Rosenheck R. Impact of a program encouraging the use of generic antipsychotics. Am J Manag Care 2012;18:e307-314.
6. Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000;20:695-8.
7. Hartung DM, Wisdom JP, Pollack DA, et al. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 2008;69:1540-7.
8. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
9. Williams SG, Alinejad NA, Williams JA, Cruess DF. Statistically significant increase in weight caused by low-dose quetiapine. Pharmacotherapy 2010;30:1011-5.
10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005;294:1934-43.
11. Guardia J, Roncero C, Galan J, Gonzalvo B, Burguete T, Casas M. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcoholdependent patients. Addict Behav 2011;36:265-9.